Bipin N Savani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3978149/publications.pdf Version: 2024-02-01



RIDIN N SAVANI

#	Article	IF	CITATIONS
1	Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood, 2016, 127, 2427-2438.	1.4	403
2	Indications for Autologous and Allogeneic Hematopoietic CellÂTransplantation: Guidelines from the American Society forÂBlood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1863-1869.	2.0	342
3	Increasing Incidence of Chronic Graft-versus-Host Disease inÂAllogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2015, 21, 266-274.	2.0	331
4	Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood, 2017, 130, 1156-1164.	1.4	210
5	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. Biology of Blood and Marrow Transplantation, 2015, 21, 1167-1187.	2.0	182
6	Peripheral Blood Progenitor Cell Mobilization for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1262-1273.	2.0	176
7	The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. Bone Marrow Transplantation, 2018, 53, 521-534.	2.4	168
8	Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood, 2013, 122, 3863-3870.	1.4	153
9	Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome–positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, Cancer, 2016, 122, 2941-2951.	4.1	140
10	Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2020, 26, 1247-1256.	2.0	139
11	Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1826-1838.	2.0	135
12	Absolute Lymphocyte Count on Day 30 Is a Surrogate for Robust Hematopoietic Recovery and Strongly Predicts Outcome after T Cell-Depleted Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2007, 13, 1216-1223.	2.0	134
13	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, 2305-2321.	2.0	132
14	Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2014, 20, 89-97.	2.0	130
15	Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. Biology of Blood and Marrow Transplantation, 2016, 22, 1915-1925.	2.0	130
16	Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1729-1736.	2.0	119
17	How I treat late effects in adults after allogeneic stem cell transplantation. Blood, 2011, 117, 3002-3009.	1.4	109
18	Anti-thymocyte globulin as graft- <i>versus</i> -host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica, 2017, 102, 224-234.	3.5	108

#	Article	IF	CITATIONS
19	Hematopoletic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2019, 54,	2.4	106
20	Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1155-1166.	2.0	104
21	Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2014, 20, 402-408.e1.	2.0	98
22	Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transplantation, 2020, 55, 1114-1125.	2.4	97
23	The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. Bone Marrow Transplantation, 2020, 55, 12-24.	2.4	94
24	Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. Blood, 2015, 126, 2062-2069.	1.4	93
25	Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation, American Journal of Hematology, 2018, 93, 1142-1152	4.1	91
26	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with <i>FLT3</i> -internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica, 2020, 105, 1507-1516.	3.5	91
27	Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood, 2006, 107, 1688-1695.	1.4	90
28	Increased Risk of Cervical Dysplasia in Long-Term Survivors of Allogeneic Stem Cell Transplantation—Implications for Screening and HPV Vaccination. Biology of Blood and Marrow Transplantation, 2008, 14, 1072-1075.	2.0	89
29	Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 2117-2125.	2.0	87
30	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transplantation, 2019, 54, 1868-1880.	2.4	86
31	Lost in Transition: The Essential Need for Long-Term Follow-Up Clinic for Blood and Marrow Transplantation Survivors. Biology of Blood and Marrow Transplantation, 2015, 21, 225-232.	2.0	85
32	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, e76-e85.	2.0	85
33	Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia – a matched pair analysis by the Acute Leukaemia Working Party of EBMT. British Journal of Haematology, 2019, 184, 782-787.	2.5	82
34	Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT. Haematologica, 2015, 100, 859-869.	3.5	80
35	Improved survival after acute graft- <i>versus</i> -host disease diagnosis in the modern era. Haematologica, 2017, 102, 958-966.	3.5	79
36	Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, 2113-2123.	2.0	77

#	Article	IF	CITATIONS
37	Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. Bone Marrow Transplantation, 2018, 53, 535-555.	2.4	75
38	Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1796-1803.	2.0	73
39	Impact of preâ€transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation. Cancer, 2017, 123, 1828-1838.	4.1	73
40	Increased Risk of Bone Loss without Fracture Risk in Long-Term Survivors after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2007, 13, 517-520.	2.0	72
41	Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1636-1645.	2.0	71
42	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 726-733.	2.0	71
43	The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. Blood Advances, 2019, 3, 670-680.	5.2	71
44	Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 845-854.	2.0	69
45	Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management. Blood, 2010, 116, 1197-1204.	1.4	68
46	Conditioning Chemotherapy Dose Adjustment in Obese Patients: A Review and Position Statement by the American Society for Blood and Marrow Transplantation Practice Guideline Committee. Biology of Blood and Marrow Transplantation, 2014, 20, 600-616.	2.0	68
47	Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. Journal of Hematology and Oncology, 2020, 13, 46.	17.0	68
48	Summary of Scientific and Statistical Methods, Study Endpoints and Definitions for Observational and Registry-Based Studies in Hematopoietic Cell Transplantation. Clinical Hematology International, 2020, 2, 2.	1.7	66
49	Female Long-Term Survivors After Allogeneic Hematopoietic Stem Cell Transplantation: Evaluation and Management. Seminars in Hematology, 2012, 49, 83-93.	3.4	65
50	Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 971-983.	2.0	65
51	Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. Transplantation and Cellular Therapy 2021, 27, 642-649	1.2	65
52	Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica, 2017, 102, 1810-1822.	3.5	64
53	Machine learning and artificial intelligence in haematology. British Journal of Haematology, 2021, 192, 239-250.	2.5	64
54	Survival following allogeneic transplant in patients with myelofibrosis. Blood Advances, 2020, 4, 1965-1973.	5.2	63

#	Article	IF	CITATIONS
55	Overview of approved CARâ€∓ therapies, ongoing clinical trials, and its impact on clinical practice. EJHaem, 2022, 3, 6-10.	1.0	63
56	Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. Cancer, 2018, 124, 2541-2551.	4.1	61
57	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1975-1983.	2.0	61
58	Chronic GVHD and Pretransplantation Abnormalities in Pulmonary Function Are the Main Determinants Predicting Worsening Pulmonary Function in Long-term Survivors after Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2006, 12, 1261-1269.	2.0	60
59	Randomized Double-Blind Study of the Safety and Immunogenicity of Standard-Dose Trivalent Inactivated Influenza Vaccine versus High-Dose Trivalent Inactivated Influenza Vaccine in Adult Hematopoietic Stem Cell Transplantation Patients. Biology of Blood and Marrow Transplantation, 2016. 22. 528-535.	2.0	60
60	Allogeneic haematopoietic cell transplantation for extranodal natural killer/Tâ€cell lymphoma, nasal type: a <scp>CIBMTR</scp> analysis. British Journal of Haematology, 2018, 182, 916-920.	2.5	59
61	Prediction and prevention of transplant-related mortality from pulmonary causes after total body irradiation and allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation, 2005, 11, 223-230.	2.0	58
62	Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide–Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2019, 25, 1859-1868.	2.0	58
63	Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT. Journal of Hematology and Oncology, 2016, 9, 25.	17.0	57
64	CAR T cell therapy in solid tumors: A review of current clinical trials. EJHaem, 2022, 3, 24-31.	1.0	57
65	Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. Biology of Blood and Marrow Transplantation, 2016, 22, 1493-1503.	2.0	55
66	Sources of Hematopoietic Stem and Progenitor Cells and Methods to Optimize Yields for Clinical Cell Therapy. Biology of Blood and Marrow Transplantation, 2017, 23, 1241-1249.	2.0	55
67	Optimizing Antithymocyte Globulin Dosing for Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Based on Recipient Absolute Lymphocyte Count. Biology of Blood and Marrow Transplantation, 2018, 24, 150-155.	2.0	55
68	Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2019, 54, 519-530.	2.4	54
69	Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation. American Journal of Hematology, 2018, 93, 246-253.	4.1	52
70	Immune-Mediated Complications after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1368-1375.	2.0	51
71	Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. Haematologica, 2020, 105, 47-58.	3.5	51
72	Second Solid Cancers after Allogeneic Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning. Biology of Blood and Marrow Transplantation, 2014, 20, 1777-1784.	2.0	50

#	Article	IF	CITATIONS
73	Sexual health in hematopoietic stem cell transplant recipients. Cancer, 2015, 121, 4124-4131.	4.1	50
74	Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation. Journal of Hematology and Oncology, 2016, 9, 118.	17.0	50
75	Long-Term Survival and Late Effects among One-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Acute Leukemia and Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2015, 21, 151-158.	2.0	49
76	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Developing Recommendations to Improve Survivorship and Long-Term Outcomes. Biology of Blood and Marrow Transplantation, 2017, 23, 6-9.	2.0	49
77	The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. Biology of Blood and Marrow Transplantation, 2015, 21, 1746-1753.	2.0	48
78	Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplantation, 2019, 54, 662-673.	2.4	48
79	Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1961-1964.	2.0	47
80	Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. Leukemia Research, 2018, 74, 130-136.	0.8	47
81	CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. Leukemia, 2019, 33, 2767-2778.	7.2	47
82	Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2019, 54, 1254-1265.	2.4	47
83	Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis. Lancet Haematology,the, 2015, 2, e384-e392.	4.6	46
84	The use of venetoclaxâ€based salvage therapy for postâ€hematopoietic cell transplantation relapse of acute myeloid leukemia. American Journal of Hematology, 2020, 95, 1006-1014.	4.1	45
85	Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. Transplantation and Cellular Therapy, 2021, 27, 6-20.	1.2	45
86	Longâ€ŧerm outcomes among 2â€year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large bâ€cell lymphoma. Cancer, 2018, 124, 816-825.	4.1	44
87	Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. Biology of Blood and Marrow Transplantation, 2018, 24, 1406-1414.	2.0	44
88	Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation. JAMA Oncology, 2019, 5, 715.	7.1	44
89	Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors. Journal of Hematology and Oncology, 2020, 13, 87.	17.0	44
90	Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. Haematologica, 2017, 102, 1823-1832.	3.5	43

#	Article	lF	CITATIONS
91	Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT. Haematologica, 2016, 101, 256-262.	3.5	42
92	Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. Biology of Blood and Marrow Transplantation, 2017, 23, 767-775.	2.0	41
93	Low CD34 Dose Is Associated with Poor Survival after Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2014, 20, 1418-1425.	2.0	40
94	RIC <i>versus</i> MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT. Oncotarget, 2016, 7, 43027-43038.	1.8	40
95	Impact of ABO incompatibility on patients' outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT. Haematologica, 2017, 102, 1066-1074.	3.5	40
96	Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 362-368.	2.0	40
97	Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years. Clinical Cancer Research, 2020, 26, 6475-6482.	7.0	40
98	Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. Blood Cancer Journal, 2020, 10, 26.	6.2	40
99	Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission. Oncotarget, 2018, 9, 3379-3393.	1.8	40
100	Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation. 2018. 24. 751-757.	2.0	39
101	Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age. Biology of Blood and Marrow Transplantation, 2017, 23, 1327-1334.	2.0	38
102	Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation. 2017. 23, 278-284.	2.0	38
103	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report. Biology of Blood and Marrow Transplantation, 2017, 23, 870-881.	2.0	38
104	Can Routine Posttransplant HPV Vaccination Prevent Commonly Occurring Epithelial Cancers after Allogeneic Stem Cell Transplantation?. Clinical Cancer Research, 2009, 15, 2219-2221.	7.0	37
105	Allotransplantation for Patients Age ≥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. Biology of Blood and Marrow Transplantation, 2014, 20, 960-968.	2.0	37
106	Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma. Biology of Blood and Marrow Transplantation, 2014, 20, 951-959.	2.0	37
107	Preparative Regimen Dosing for Hematopoietic Stem Cell Transplantation in Patients with Chronic Kidney Disease: Analysis of the Literature and Recommendations. Biology of Blood and Marrow Transplantation, 2014, 20, 908-919.	2.0	37
108	Longâ€term outcome after a treosulfanâ€based conditioning regimen for patients with acute myeloid leukemia: A report from the <scp>A</scp> cute <scp>L</scp> eukemia <scp>W</scp> orking <scp>P</scp> arty of the <scp>E</scp> uropean <scp>S</scp> ociety for <scp>B</scp> lood and <scp>M</scp> arrow <scp>T</scp> ransplantation. Cancer, 2017, 123, 2671-2679.	4.1	37

#	Article	IF	CITATIONS
109	Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Advances, 2019, 3, 3123-3131.	5.2	37
110	Graftâ€ <i>versus</i> â€host disease risk after chimeric antigen receptor Tâ€cell therapy: the diametric opposition of T cells. British Journal of Haematology, 2021, 195, 660-668.	2.5	37
111	Time to Consider HPV Vaccination after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 1033-1036.	2.0	36
112	Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. Journal of Clinical Oncology, 2020, 38, 2062-2076.	1.6	36
113	Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2021, 56, 532-535.	2.4	36
114	Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia. Bone Marrow Transplantation, 2022, 57, 215-223.	2.4	36
115	Prolonged Chronic Graft-versus-Host Disease is a Risk Factor for Thyroid Failure in Long-Term Survivors After Matched Sibling Donor Stem Cell Transplantation for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2009, 15, 377-381.	2.0	35
116	Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT. Haematologica, 2016, 101, 773-780.	3.5	35
117	Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. Blood Advances, 2018, 2, 2922-2936.	5.2	35
118	Comparative Analysis of Calcineurin Inhibitor–Based Methotrexate and Mycophenolate Mofetil–Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 73-85.	2.0	35
119	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Advances, 2022, 6, 339-357.	5.2	35
120	Post-Transplant Outcomes in High-Risk Compared with Non–High-Risk Multiple Myeloma: A CIBMTR Analysis. Biology of Blood and Marrow Transplantation, 2016, 22, 1893-1899.	2.0	34
121	Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. Biology of Blood and Marrow Transplantation, 2018, 24, 521-528.	2.0	34
122	Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study. Blood Advances, 2018, 2, 2127-2135.	5.2	34
123	Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis. Blood, 2021, 137, 556-568.	1.4	34
124	Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. Biology of Blood and Marrow Transplantation, 2014, 20, 202-208.	2.0	33
125	Avascular Necrosis of Bone after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents. Biology of Blood and Marrow Transplantation, 2014, 20, 587-592.	2.0	33
126	New Cancers after Autotransplantations for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2015, 21, 738-745.	2.0	33

#	Article	IF	CITATIONS
127	High-Dose Total Body Irradiation and Myeloablative Conditioning before Allogeneic Hematopoietic Cell Transplantation: Time to Rethink?. Biology of Blood and Marrow Transplantation, 2015, 21, 620-624.	2.0	33
128	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. Biology of Blood and Marrow Transplantation, 2016, 22, 248-257.	2.0	33
129	Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party. Journal of Hematology and Oncology, 2017. 10. 31.	17.0	33
130	ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors. Biology of Blood and Marrow Transplantation, 2018, 24, 1119-1124.	2.0	33
131	Role of Physical Therapy before and after Hematopoietic Stem Cell Transplantation: White Paper Report. Biology of Blood and Marrow Transplantation, 2019, 25, e191-e198.	2.0	33
132	Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies. Annals of Medicine, 2016, 48, 428-439.	3.8	32
133	Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen. Clinical Cancer Research, 2018, 24, 2794-2803.	7.0	32
134	Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. Bone Marrow Transplantation, 2021, 56, 218-224.	2.4	32
135	Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. JAMA Oncology, 2022, 8, 404.	7.1	32
136	Vitamin D deficiency, autoimmunity, and graft-versus-host-disease risk: Implication for preventive therapy. Experimental Hematology, 2012, 40, 263-267.	0.4	31
137	Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. British Journal of Haematology, 2019, 186, 767-776.	2.5	31
138	Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center. Cancer, 2018, 124, 2134-2141.	4.1	30
139	Comprehensive Prognostication in Critically III Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries. Biology of Blood and Marrow Transplantation, 2020, 26. 333-342.	2.0	30
140	Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia. Leukemia, 2020, 34, 2766-2775.	7.2	30
141	Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia. Haematologica, 2021, 106, 1591-1598.	3.5	29
142	How Can We Improve Life Expectancy and Quality of Life in Long-Term Survivors After Allogeneic Stem Cell Transplantation?. Seminars in Hematology, 2012, 49, 1-3.	3.4	28
143	Prediction of Hematopoietic Stem Cell Transplantation Related Mortality- Lessons Learned from the In-Silico Approach: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party Data Mining Study. PLoS ONE, 2016, 11, e0150637.	2.5	28
144	Time to Explore Preventive and Novel Therapies for Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 1479-1487.	2.0	27

#	Article	IF	CITATIONS
145	Extracorporeal photopheresis as second-line treatment for acute graft-versus-host disease: impact on six-month freedom from treatment failure. Haematologica, 2014, 99, 1746-1752.	3.5	27
146	Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. Blood Advances, 2018, 2, 933-940.	5.2	27
147	How do we plan hematopoietic cell transplant and cellular therapy with the looming COVIDâ€19 threat?. British Journal of Haematology, 2020, 189, 239-240.	2.5	27
148	Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT. Journal of Hematology and Oncology, 2021, 14, 84.	17.0	27
149	Male survivors of allogeneic hematopoietic stem cell transplantation have a long term persisting risk of cardiovascular events. Experimental Hematology, 2014, 42, 83-89.	0.4	26
150	Race and Ethnicity Influences Collection of Granulocyte Colony–Stimulating Factor–Mobilized Peripheral Blood Progenitor Cells from Unrelated Donors, a Center for International Blood and Marrow Transplant Research Analysis. Biology of Blood and Marrow Transplantation, 2015, 21, 165-171.	2.0	26
151	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis. Biology of Blood and Marrow Transplantation, 2016, 22, 1056-1064.	2.0	26
152	Preventing Measles in Immunosuppressed Cancer and Hematopoietic Cell Transplantation Patients: A Position Statement by the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, e321-e330.	2.0	26
153	Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT), Journal of Hematology and Oncology, 2019, 12, 44.	17.0	26
154	Postâ€ŧransplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLAâ€identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2021, 127, 209-218.	4.1	26
155	Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. Lancet Haematology,the, 2021, 8, e205-e215.	4.6	26
156	Pretransplant pulmonary function tests predict risk of mortality following fractionated total body irradiation and allogeneic peripheral blood stem cell transplant. International Journal of Radiation Oncology Biology Physics, 2006, 66, 520-527.	0.8	25
157	Minimal Residual Disease in Myeloma: Are We There Yet?. Biology of Blood and Marrow Transplantation, 2012, 18, 1790-1799.	2.0	25
158	Epigenetic landscape of the <i><scp>TERT</scp></i> promoter: a potential biomarker for high risk <scp>AML</scp> / <scp>MDS</scp> . British Journal of Haematology, 2016, 175, 427-439.	2.5	25
159	Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2018, 53, 1278-1287.	2.4	25
160	Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT. Bone Marrow Transplantation, 2019, 54, 1987-1994.	2.4	25
161	Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT. Leukemia, 2020, 34, 87-99.	7.2	25
162	Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia. Clinical Cancer Research, 2021, 27, 843-851.	7.0	25

#	Article	IF	CITATIONS
163	How can we reduce hepatic veno-occlusive disease–related deaths after allogeneic stem cell transplantation?. Experimental Hematology, 2012, 40, 513-517.	0.4	24
164	Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Annals of Hematology, 2019, 98, 2389-2398.	1.8	24
165	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. Haematologica. 2020. 105. 1329-1338.	3.5	23
166	Recovery of spermatogenesis after total-body irradiation. Blood, 2006, 108, 4292-4294.	1.4	22
167	Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant Research. Haematologica, 2016, 101, 1267-1274.	3.5	22
168	Varicella Zoster Virus Reactivation in Adult Survivors of Hematopoietic Cell Transplantation: How Do We Best Protect Our Patients?. Biology of Blood and Marrow Transplantation, 2018, 24, 1783-1787.	2.0	22
169	Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) study. American Journal of Hematology, 2018, 93, 769-777.	4.1	22
170	Survival outcomes of allogeneic hematopoietic cell transplants with EBVâ€positive or EBVâ€negative postâ€transplant lymphoproliferative disorder, A CIBMTR study. Transplant Infectious Disease, 2019, 21, e13145.	1.7	22
171	The role of nutrition and effects on the cytokine milieu in allogeneic hematopoietic stem cell transplantation. Cellular Immunology, 2012, 276, 6-9.	3.0	21
172	Peripheral blood stem cell versus bone marrow transplantation: A perspective from the Acute Leukemia Working Party of the European Society forÂBloodÂand Marrow Transplantation. Experimental Hematology, 2016, 44, 567-573.	0.4	21
173	European Group for Blood and Marrow Transplantation Centers with FACT-JACIE Accreditation Have Significantly Better Compliance with Related Donor Care Standards. Biology of Blood and Marrow Transplantation, 2016, 22, 514-519.	2.0	21
174	Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT. Journal of Hematology and Oncology, 2017, 10, 128.	17.0	21
175	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. Biology of Blood and Marrow Transplantation, 2020, 26, 472-479.	2.0	21
176	ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. Bone Marrow Transplantation, 2021, 56, 2911-2921.	2.4	21
177	Measuring Immune Response to Commonly Used Vaccinations in Adult Recipients of Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1614-1621.	2.0	20
178	Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia. American Journal of Hematology, 2018, 93, 1211-1219.	4.1	20
179	Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update. Expert Review of Hematology, 2014, 7, 301-315.	2.2	19
180	Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis. Bone Marrow Transplantation, 2019, 54, 531-539.	2.4	19

#	Article	IF	CITATIONS
181	Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement. Biology of Blood and Marrow Transplantation, 2019, 25, 1890-1897.	2.0	19
182	Personalizing rabbit anti-thymocyte globulin therapy for prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation: is there an optimal dose?. Bone Marrow Transplantation, 2020, 55, 505-522.	2.4	19
183	Geographic Distance Is Not Associated with Inferior Outcome When Using Long-Term Transplant Clinic Strategy. Biology of Blood and Marrow Transplantation, 2014, 20, 53-57.	2.0	18
184	Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2019, 25, 683-688.	2.0	18
185	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Advances, 2020, 4, 3180-3190.	5.2	18
186	<scp>CD34</scp> + cell dose effects on clinical outcomes after Tâ€cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working Party of the European Society for blood and marrow transplantation (<scp>EBMT</scp>). American Journal of Hematology, 2020, 95, 892-899.	4.1	18
187	Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis. Bone Marrow Transplantation, 2022, 57, 911-917.	2.4	18
188	The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50Âyears—a report from the EBMT acute leukemia working party. Journal of Hematology and Oncology, 2016, 9, 65.	17.0	17
189	ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT. American Journal of Hematology, 2017, 92, 789-796.	4.1	17
190	Impact of conditioning intensity on outcomes of haploidentical stem cell transplantation for patients with acute myeloid leukemia 45 years of age and over. Cancer, 2019, 125, 1499-1506.	4.1	17
191	FLAMSA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26,	2.0	17
192	Second allogeneic haematopoietic cell transplantation using HLAâ€matched unrelated <i>versus</i> Tâ€cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. British Journal of Haematology, 2021, 193, 592-601.	2.5	17
193	Outcomes of rituximabâ€BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. Cancer, 2020, 126, 2279-2287.	4.1	17
194	Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia. Cancers, 2022, 14, 497.	3.7	17
195	Impact of risk score calculations in choosing frontâ€line tyrosine kinase inhibitors for patients with newly diagnosed chronic myeloid leukemia in the chronic phase. European Journal of Haematology, 2014, 93, 179-186.	2.2	16
196	Haploidentical transplantation: selecting optimal conditioning regimen and stem cell source. Seminars in Hematology, 2016, 53, 111-114.	3.4	16
197	Metabolic Complications Precede Alloreactivity and Are Characterized by Changes in Suppression of Tumorigenicity 2 Signaling. Biology of Blood and Marrow Transplantation, 2017, 23, 529-532.	2.0	16
198	Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma. Bone Marrow Transplantation, 2018, 53, 701-707.	2.4	16

#	Article	IF	CITATIONS
199	Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B ell lymphomas in first remission in the rituximab era: A systematic review and metaâ€analysis. Cancer, 2019, 125, 4417-4425.	4.1	16
200	Comparative outcomes of myeloablative and reducedâ€intensity conditioning allogeneic hematopoietic cell transplantation for therapyâ€related acute myeloid leukemia with prior solid tumor: A report from the acute leukemia working party of the European society for blood and bone marrow transplantation. American Journal of Hematology, 2019, 94, 431-438	4.1	16
201	Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow	2.0	16
202	A perspective on complementary/alternative medicine use among survivors of hematopoietic stem cell transplant: Benefits and uncertainties. Cancer, 2015, 121, 2303-2313.	4.1	15
203	Spiritual Well-Being in Hispanic and Non-Hispanic Survivors of Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Psychosocial Oncology, 2015, 33, 635-654.	1.2	15
204	Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. Transplantation and Cellular Therapy, 2021, 27, 68.e1-68.e9.	1.2	15
205	Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. Transplantation and Cellular Therapy, 2021, 27, 923.e1-923.e12.	1.2	15
206	Current Status and Perspectives of Irradiation-Based Conditioning Regimens for Patients with Acute Leukemia Undergoing Hematopoietic Stem Cell Transplantation. Clinical Hematology International, 2019, 1, 19.	1.7	15
207	Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis. Clinical Cancer Research, 2022, 28, 4258-4266.	7.0	15
208	How we manage <scp>JAK</scp> inhibition in allogeneic transplantation for myelofibrosis. European Journal of Haematology, 2015, 94, 115-119.	2.2	14
209	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1875-1883.	2.0	14
210	Survival Trends in Infants Undergoing Allogeneic Hematopoietic Cell Transplant. JAMA Pediatrics, 2019, 173, e190081.	6.2	14
211	Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplantation, 2019, 54, 648-661.	2.4	14
212	Comparison of outcomes of HCT in blast phase of <i>BCR-ABL1</i> â^' MPN with de novo AML and with AML following MDS. Blood Advances, 2020, 4, 4748-4757.	5.2	14
213	Impact of total body irradiationâ€vs chemotherapyâ€based myeloablative conditioning on outcomes of haploidentical hematopoietic cell transplantation for acute myelogenous leukemia. American Journal of Hematology, 2020, 95, 1200-1208.	4.1	14
214	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2020, 26, 2139-2146.	2.0	14
215	Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. Blood Advances, 2020, 4, 2084-2094.	5.2	14
216	Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2020, 26, 1784-1802.	2.0	14

#	Article	IF	CITATIONS
217	Securing the graft during pandemic: are we ready for cryopreservation for all?. Biology of Blood and Marrow Transplantation, 2020, 26, e145-e146.	2.0	14
218	Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib. Lancet Oncology, The, 2005, 6, 809-812.	10.7	13
219	Repair of Impaired Pulmonary Function Is Possible in Very-Long-Term Allogeneic Stem Cell Transplantation Survivors. Biology of Blood and Marrow Transplantation, 2014, 20, 209-213.	2.0	13
220	The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time. Biology of Blood and Marrow Transplantation, 2019, 25, 1325-1330.	2.0	13
221	Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2020, 26, 553-561.	2.0	13
222	The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor Tâ€cell therapy. British Journal of Haematology, 2021, 193, 1060-1075.	2.5	13
223	Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 410-422.	1.2	13
224	Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation. Transplantation and Cellular Therapy, 2022, 28, 86.e1-86.e8.	1.2	13
225	Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis. Transplantation and Cellular Therapy, 2022, 28, 681-693.	1.2	13
226	Outcomes of autologous or allogeneic stem cell transplantation for non-Hodgkin lymphoma. Experimental Hematology, 2014, 42, 39-45.	0.4	12
227	Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation. Biology of Blood and Marrow Transplantation, 2015, 21, 552-558.	2.0	12
228	Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are More Common at Low-Volume Bone Marrow Collection Centers. Biology of Blood and Marrow Transplantation, 2015, 21, 1830-1838.	2.0	12
229	Reduced Relapse Incidence with FLAMSA–RIC Compared with Busulfan/Fludarabine for Acute Myelogenous Leukemia Patients in First or Second Complete Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 2224-2232.	2.0	12
230	Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. Biology of Blood and Marrow Transplantation, 2019, 25, 1099-1106.	2.0	12
231	GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. Blood Advances, 2019, 3, 1441-1449.	5.2	12
232	The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation. Leukemia, 2020, 34, 1144-1153.	7.2	12
233	Graftâ€versusâ€host disease and graftâ€versusâ€leukaemia effects in secondary acute myeloid leukaemia: a retrospective, multicentre registry analysis from the Acute Leukaemia Working Party of the EBMT. British Journal of Haematology, 2020, 188, 428-437.	2.5	12
234	Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States. Cancer, 2021, 127, 609-618.	4.1	12

#	Article	IF	CITATIONS
235	Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia. Journal of Hematology and Oncology, 2021, 14, 76.	17.0	12
236	Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan after Allogeneic Stem Cell Transplantation for B Cell Malignancies. Biology of Blood and Marrow Transplantation, 2016, 22, 1801-1807.	2.0	11
237	Defining Incidence and Risk Factors for Catheter-Associated Bloodstream Infections in an Outpatient Adult Hematopoietic Cell Transplantation Program. Biology of Blood and Marrow Transplantation, 2018, 24, 2081-2087.	2.0	11
238	Transplant outcomes for patients with therapy-related acute myeloid leukemia with prior lymphoid malignancy: an ALWP of EBMT study. Bone Marrow Transplantation, 2020, 55, 224-232.	2.4	11
239	Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield. Blood Advances, 2020, 4, 706-716.	5.2	11
240	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. Transplantation and Cellular Therapy, 2021, 27, 921.e1-921.e10.	1.2	11
241	Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 310-320.	1.2	11
242	Management of Relapses After Hematopoietic Cell Transplantation in T-Cell Non-Hodgkin Lymphomas. Seminars in Hematology, 2014, 51, 73-86.	3.4	10
243	Risk Factors for Subsequent Central Nervous System Tumors in Pediatric Allogeneic Hematopoietic Cell Transplant: A Study from the Center for International Blood and Marrow Transplant Research (CIBMTR). Biology of Blood and Marrow Transplantation, 2017, 23, 1320-1326.	2.0	10
244	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. Clinical Cancer Research, 2019, 25, 5143-5155.	7.0	10
245	Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1744-1755.	2.0	10
246	Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 480-487.	2.0	10
247	Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning―for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation, 2021, 56, 481-491.	2.4	10
248	Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT. Bone Marrow Transplantation, 2021, 56, 2194-2202.	2.4	10
249	Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States. Transplantation and Cellular Therapy, 2021, 27, 679.e1-679.e8.	1.2	10
250	Achieving early molecular response in chronic myeloid leukemia in chronic phase to reduce the risk of progression: clinical relevance of the 3―and 6â€month time points. European Journal of Haematology, 2015, 95, 103-112.	2.2	9
251	Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. Biology of Blood and Marrow Transplantation, 2018, 24, 78-85.	2.0	9
252	Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI. Blood Advances, 2019, 3, 1950-1960.	5.2	9

#	Article	IF	CITATIONS
253	Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia. Bone Marrow Transplantation, 2021, 56, 622-634.	2.4	9
254	Improved Outcomes of Haploidentical Hematopoietic Cell Transplantation with Total Body Irradiation-Based Myeloablative Conditioning in Acute Lymphoblastic Leukemia. Transplantation and Cellular Therapy, 2021, 27, 171.e1-171.e8.	1.2	9
255	Refusing blood transfusions from COVIDâ€19â€vaccinated donors: are we repeating history?. British Journal of Haematology, 2022, 196, 585-588.	2.5	9
256	Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies. British Journal of Haematology, 2022, 197, 28-40.	2.5	9
257	Role of bridging therapy during chimeric antigen receptor T cell therapy. EJHaem, 2022, 3, 39-45.	1.0	9
258	Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation, 2022, 57, 399-406.	2.4	9
259	Early lymphocyte reconstitution is associated with improved transplant outcome after cord blood transplantation. Cytotherapy, 2011, 13, 78-82.	0.7	8
260	Preparative Regimen Dosing for Hematopoietic Stem Cell Transplantation in Patients with Chronic Hepatic Impairment: Analysis of the Literature and Recommendations. Biology of Blood and Marrow Transplantation, 2014, 20, 622-629.	2.0	8
261	ASBMT Statement on Routine Prophylaxis for Central Nervous System Recurrence of Acute Lymphoblastic Leukemia following Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, e86-e88.	2.0	8
262	Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party. Bone Marrow Transplantation, 2021, 56, 917-927.	2.4	8
263	Clinical and biological predictors of outcome following relapse of CML post-allo-SCT. Bone Marrow Transplantation, 2015, 50, 189-196.	2.4	7
264	Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less. Biology of Blood and Marrow Transplantation, 2018, 24, 175-184.	2.0	7
265	Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. Leukemia and Lymphoma, 2020, 61, 2811-2820.	1.3	7
266	Impact of autologous blood transfusion after bone marrow harvest on unrelated donor's health and outcome: a CIBMTR analysis. Bone Marrow Transplantation, 2020, 55, 2121-2131.	2.4	7
267	Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma. Bone Marrow Transplantation, 2020, 55, 1137-1146.	2.4	7
268	Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT). Cancer Medicine, 2021, 10, 23-33.	2.8	7
269	American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma. Transplantation and Cellular Therapy, 2021, 27, 720-728.	1.2	7
270	Managing Endocrine Disorders in Adults After Hematopoietic Stem Cell Transplantation. Clinical Hematology International, 2019, 1, 180.	1.7	7

#	Article	IF	CITATIONS
271	Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT. Bone Marrow Transplantation, 2022, 57, 1421-1427.	2.4	7
272	Comparison of Outcomes after Unrelated Double-Unit Cord Blood and Haploidentical Peripheral Blood Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia: A Study on Behalf of Eurocord and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Transplantation and Cellular Therapy, 2022, 28, 710.e1-710.e10.	1.2	7
273	Establishing an autologous versus allogeneic hematopoietic cell transplant program in nations with emerging economies. Hematology/ Oncology and Stem Cell Therapy, 2017, 10, 173-177.	0.9	6
274	Follow-up issues in survivors of hematologic malignancies – Current stance and future perspectives. Blood Reviews, 2020, 44, 100674.	5.7	6
275	American Society for Transplantation and Cellular Therapy Infectious Disease Guidelines: Preface to the Series. Transplantation and Cellular Therapy, 2021, 27, 103-104.	1.2	6
276	Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program. Transplantation and Cellular Therapy, 2021, 27, 267.e1-267.e5.	1.2	6
277	Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT. Bone Marrow Transplantation, 2021, 56, 2445-2453.	2.4	6
278	Chimeric antigen receptor Tâ€cell therapy: Challenges and framework of outpatient administration. EJHaem, 2022, 3, 54-60.	1.0	6
279	Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party. Bone Marrow Transplantation, 2022, 57, 1269-1276.	2.4	6
280	Prospective trial of minimal residual disease assessment by multiparametric flow cytometry for multiple myeloma in the era of bortezomib-based chemotherapy. Bone Marrow Transplantation, 2018, 53, 1589-1592.	2.4	5
281	Advances in gene therapy for hematologic disease and considerations for transfusion medicine. Seminars in Hematology, 2020, 57, 83-91.	3.4	5
282	Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 296-304.	0.4	5
283	Taking a BiTE out of the CAR T space race. British Journal of Haematology, 2021, 195, 689-697.	2.5	5
284	Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms. EJHaem, 2021, 2, 607-615.	1.0	5
285	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>KMT2A</i> -rearranged AML. Blood Advances, 2022, 6, 828-847.	5.2	5
286	Impact of KIR and HLA Genotypes on Outcome in Nonmyeloablative Hematopoietic Cell Transplantation (HCT) Using HLA Matched Related Donors Blood, 2006, 108, 323-323.	1.4	5
287	A Suppressive Microenvironment in Acute Myeloid Leukemia Induces Global Alteration of T and NK Cell Profiles - Evidence for Immune-Editing Effect By Leukemia. Blood, 2014, 124, 1047-1047.	1.4	5
288	Interaction Between Post-Transplant Diabetes Mellitus and Regulatory T Cell Phenotype. Blood, 2011, 118, 3039-3039.	1.4	5

#	ARTICLE	IF	CITATIONS
289	from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Transplantation and Cellular Therapy, 2022, 28,	1.2	5
290	boble roots enzy Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia. Bone Marrow Transplantation, 2022, 57, 1116-1123.	2.4	5
291	Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. Blood Advances, 2022, 6, 3991-3995.	5.2	5
292	Transplant to treatment-free remission: the evolving view of â€~cure' in chronic myeloid leukemia. Expert Review of Hematology, 2015, 8, 785-797.	2.2	4
293	Making inroads to the cure: Barriers to clinical trial enrollment in hematopoietic cell transplantation. Clinical Transplantation, 2017, 31, e12948.	1.6	4
294	Leveraging JAK-STAT regulation in myelofibrosis to improve outcomes with allogeneic hematopoietic stem-cell transplant. Therapeutic Advances in Hematology, 2018, 9, 251-259.	2.5	4
295	Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (≥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT. Bone Marrow Transplantation, 2020, 55, 729-739.	2.4	4
296	Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors. Biology of Blood and Marrow Transplantation, 2020, 26, 1210-1217.	2.0	4
297	Understanding basic steps to hematopoietic stem cell transplantation evaluation. American Journal of Blood Research, 2013, 3, 102-6.	0.6	4
298	Immunomodulatory nonablative conditioning regimen for B-cell lymphoidÂmalignancies. Experimental Hematology, 2012, 40, 431-435.	0.4	3
299	â€~To treat or not to treat': raising awareness on the effects of graft versus host disease drugs on musculoskeletal system. Bone Marrow Transplantation, 2018, 53, 909-912.	2.4	3
300	Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study. Biology of Blood and Marrow Transplantation, 2018, 24, 486-493.	2.0	3
301	Leukaemia risk associated with low-dose radiation. Lancet Haematology,the, 2018, 5, e324-e325.	4.6	3
302	Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia – a study of the Acute Leukemia Working Party of the EBMT. Leukemia and Lymphoma, 2021, 62, 399-409.	1.3	3
303	Outcomes of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning Regimen in Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide for Acute Lymphoblastic Leukemia: ALWP of the EBMT Study. Blood, 2019, 134, 320-320.	1.4	3
304	Expanded Comorbidity Definitions Improve Applicability of the Hematopoietic Stem Cell Transplantation-Comorbidity Index for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Stem Cell Transplantation. Blood, 2020, 136, 34-35.	1.4	3
305	Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. Transplantation and Cellular Therapy, 2022, 28, 187.e1-187.e10.	1.2	3
306	Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia. Bone Marrow Transplantation, 2022, 57, 874-880.	2.4	3

#	Article	IF	CITATIONS
307	Can we modify transplant outcome by improving lymphocyte recovery?. Cytotherapy, 2011, 13, 900-902.	0.7	2
308	Introduction: Why alternative donor transplantation and what are the different options and current challenges?. Seminars in Hematology, 2016, 53, 55-56.	3.4	2
309	Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis. Biology of Blood and Marrow Transplantation, 2018, 24, 1928-1935.	2.0	2
310	Outcomes of a novel rituximab-based non-myeloablative conditioning regimen for hematopoietic cell transplantation in severe aplastic anemia. Bone Marrow Transplantation, 2018, 53, 795-799.	2.4	2
311	A retrospective cost analysis of the frequency and cost of transfusion premedications. Transfusion, 2019, 59, 2523-2527.	1.6	2
312	Transgender individuals represent an overlooked population amongst stem cell donors. Bone Marrow Transplantation, 2019, 54, 1721-1722.	2.4	2
313	Allogeneic haematopoietic cell transplantation after CAR Tâ€cell therapy: safe, effective and contentious. British Journal of Haematology, 2020, 189, 21-23.	2.5	2
314	Risk factors associated with early viral reactivation following haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide: a pilot study. Annals of Hematology, 2020, 99, 1137-1139.	1.8	2
315	Shorter Interdonation Interval Contributes to Lower Cell Counts in Subsequent Stem Cell Donations. Transplantation and Cellular Therapy, 2021, 27, 503.e1-503.e8.	1.2	2
316	Leukemia-Associated Antigen Specific T-Cell Responses Following Combined PR1 and WT1 Peptide Vaccination in Patients with Myeloid Malignancies Blood, 2007, 110, 287-287.	1.4	2
317	Prediction of Allogeneic HSCT Related Mortality in Acute Leukemia: Exploring Boundaries of Prediction through Machine Learning Based Modeling. a Data Mining Study from the Acute Leukemia Working Party (ALWP) of the EBMT. Blood, 2014, 124, 2568-2568.	1.4	2
318	Management of Sickle Cell Intrahepatic Cholestasis: An Argument in Favor of Automated Exchange Transfusion. Clinical Hematology International, 2019, 1, 127-133.	1.7	2
319	New indications and platforms for CARâ€∓ therapy in lymphomas beyond DLBCL. EJHaem, 2022, 3, 11-23.	1.0	2
320	Reduction in the Prevalence of Thrombotic Events in Sickle Cell Disease after Allogeneic Hematopoietic Transplantation. Transplantation and Cellular Therapy, 2022, 28, 277.e1-277.e6.	1.2	2
321	Worldwide Network for Blood and Marrow Transplantation Special Article on Key Elements in Quality and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy. Transplantation and Cellular Therapy, 2022, 28, 455-462.	1.2	2
322	Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Bone Marrow Transplantation, 2022, 57, 1150-1163.	2.4	2
323	Ferritin and FerriScan in HCT recipients. Blood, 2013, 122, 1539-1541.	1.4	1
324	Early Th1 immunity promotes immune tolerance and may impair graft-versus-leukemia effect after allogeneic hematopoietic cell transplantation. Haematologica, 2016, 101, e204-e208.	3.5	1

#	Article	IF	CITATIONS
325	Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. Bone Marrow Transplantation, 2018, 53, 932-937.	2.4	1
326	Prognostic scoring system after transplantation in myeloma: predicting early relapse. British Journal of Haematology, 2020, 191, 323-324.	2.5	1
327	Improving the Odds. Biology of Blood and Marrow Transplantation, 2020, 26, e173-e174.	2.0	1
328	Decision-analytic modeling as a tool for selecting optimal therapy incorporating hematopoietic stem cell transplantation in patients with hematological malignancy. Bone Marrow Transplantation, 2020, 55, 1220-1228.	2.4	1
329	The outcome of two or more HLA loci mismatched unrelated donor hematopoietic cell transplantation for acute leukemia: an ALWP of the EBMT study. Bone Marrow Transplantation, 2021, 56, 20-29.	2.4	1
330	Pure red blood cell aplasia: patient management pitfalls in major ABOâ€incompatible haematopoietic cell transplantation. British Journal of Haematology, 2021, 193, 701-702.	2.5	1
331	Predictive factors for outcome of first allogeneic transplant for elderly patients with acute lymphoblastic leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 831-840.	0.4	1
332	Finding the best haematopoietic stem cell transplant regimen for GATA2 haploinsufficiency: how close are we?. British Journal of Haematology, 2021, , .	2.5	1
333	Treosulphan versus busulphan: pros and cons. British Journal of Haematology, 2021, 195, 304-305.	2.5	1
334	Daily Routines and Guidelines: Driving, Infection Isolation, Masks, Food/Diet, Activities, Exercise, Pets, Sun Exposures, and Others. , 0, , 332-339.		1
335	Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Karnofsky Performance Status Score Equal or Lower Than 80%. a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Blood, 2019, 134, 2038-2038	1.4	1
336	Hepatitis B Reverse Seroconversion in Long Term Survivors of Allogeneic Hematopoietic Stem Cell Transplantation Blood, 2007, 110, 1978-1978.	1.4	1
337	Older Age, Use Of Myeloablative Regimens For Malignant Diseases and Chronic Graft-Versus-Host Disease Are Risk Factors For Avascular Necrosis Of Bone After Allogeneic Hematopoietic Cell Transplantation In Children and Adolescents. Blood, 2013, 122, 917-917.	1.4	1
338	Practicing Clinical Hematology During the COVID-19 Outbreak: A Challenge Like No Other. Clinical Hematology International, 2020, 2, 41.	1.7	1
339	The Post-Transplant Day 30 Lymphocyte Count Strongly Correlates with Transplanted Cd34 Dose and Is Predictive for Minimal Residual Disease and Mortality in Patients with Cml Undergoing Allogeneic Stem Cell Transplants from Matched Siblings Blood, 2004, 104, 3335-3335.	1.4	1
340	Reconstitution of Regulatory T Cells after Selective Depletion of CD25+ Host-Reactive Donor Lymphocytes from Allografts and Association with Acute Graft-Versus-Host-Disease Blood, 2005, 106, 595-595.	1.4	1
341	Long-Term T Cell Immune Reconstitution in Patients Surviving 10 or More Years after Allogeneic Stem Cell Transplantation for Hematologic Malignancies. Blood, 2008, 112, 1173-1173.	1.4	1
342	Tacrolimus Metabolism and Risk of Acute Graft Versus Host Disease. Blood, 2015, 126, 1954-1954.	1.4	1

#	Article	IF	CITATIONS
343	Looking Ahead: Clinical Hematology International Turns One. Clinical Hematology International, 2020, 2, 1.	1.7	1
344	Chimeric antigen receptorâ€T cell therapies: The changing landscape. EJHaem, 0, 3, 3.	1.0	1
345	Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation?. British Journal of Haematology, 2022, 197, 326-338.	2.5	1
346	When should we tell patients there may be no blood? Evaluating the â€~informed' consent process. British Journal of Haematology, 2022, , .	2.5	1
347	Impact of donor kinship on non-T-cell depleted haploidentical stem cell transplantation with post transplantation cyclophosphamide for acute leukemia: From the ALWP of the EBMT. Bone Marrow Transplantation, 2022, 57, 1260-1268.	2.4	1
348	Umbilical cord blood transplant: expanding the options. Expert Review of Hematology, 2013, 6, 341-342.	2.2	0
349	Bone Marrow Transplantation. Hematology/Oncology Clinics of North America, 2014, 28, xiii-xv.	2.2	0
350	Age is more than a number. Cytotherapy, 2014, 16, 287-288.	0.7	0
351	Hosting an Unruly Guest: The Impact of Late Acute and Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2016, 22, 779-780.	2.0	0
352	Who is the best relative? Optimizing haploidentical donor transplantation in lymphoma. British Journal of Haematology, 2020, 188, 601-602.	2.5	0
353	Response to Kawedia et al Letter to Editor in Response to the Article by McCune Et Al "Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement". Biology of Blood and Marrow Transplantation, 2020, 26, e235-e236.	2.0	0
354	Graftâ€versusâ€hostâ€disease does not help acute lymphoblastic leukaemia patients with measurable residual disease. British Journal of Haematology, 2020, 190, 22-23.	2.5	0
355	A stitch in time saves nine… MRDâ€based preâ€emptive therapy. British Journal of Haematology, 2020, 191, 19-20.	2.5	0
356	Risk factors for hemolytic transfusion reactions resulting from ABO and minor red cell antigen incompatibility: From mislabeled samples to stem cell transplant and sickle cell disease. Blood Reviews, 2021, 45, 100719.	5.7	0
357	Similar Outcomes in Early-Failure Steroid-Dependent Compared to Upfront Steroid Refractory Acute Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplant. Journal of Hematology (Brossard, Quebec), 2021, 10, 35-39.	1.0	0
358	The Intersection of Photopheresis and COVID-19 Vaccination. Transplantation and Cellular Therapy, 2021, 27, 278.	1.2	0
359	Alternative donor transplantation for severe aplastic anaemia in 2021: haplo donor, cord blood or both?. British Journal of Haematology, 2021, 193, 863-864.	2.5	0
360	Beyond ruxolitinib in steroidâ€refractory acute graftâ€versusâ€host disease. British Journal of Haematology, 2021, 195, 306-307.	2.5	0

#	Article	IF	CITATIONS
361	Pulmonary Function Abnormalities 5 Years or More Following Myeloablative and Non-Myeloablative Allogeneic Stem Cell Transplantation for Hematological Disorders - Impact of Chronic GVHD Blood, 2005, 106, 1116-1116.	1.4	0
362	T-Cell Depleted PBSCT Mitigates Acute GVHD, but Preserves Protective Chronic GVHD. Long Term Follow up of 138 Patients Blood, 2005, 106, 140-140.	1.4	0
363	α4β7± Regulatory T Cells (Tregs) at Engraftment Predict Long-Term Graft-Versus-Host Disease (GVHD) Outcomes Blood, 2009, 114, 2237-2237.	1.4	0
364	A High Prevalence of Obesity in Acute Promyelocytic Leukemia (APL): Is Obesity a Risk Factor for APL? Implication of Targeted Therapy to Control Obesity and APL Prevention Blood, 2009, 114, 3099-3099.	1.4	0
365	Autologous Stem Cell Transplant in Recurrent Diffuse Large B- Cell Lymphoma: Prior Rituximab Therapy Has No Impact On Early Lymphocyte Recovery and Transplant Outcome Blood, 2009, 114, 3407-3407.	1.4	0
366	Allografts Selectively Photodepleted of GvHD Causing T Cells and Followed by Low-Level Immunosuppression: A Novel Method to Improve Disease Control After HLA-Matched Sibling Transplantations Blood, 2009, 114, 515-515.	1.4	0
367	Genetic Variation In Recipient BAFF Modulates Phenotype of Chronic GvHD After HCT. Blood, 2010, 116, 215-215.	1.4	0
368	Extracorporeal Photopheresis (ECP): Effective Therapy for Steroid Dependent and Refractory Acute Graft-Versus-Host Disease (GVHD). Blood, 2011, 118, 1973-1973.	1.4	0
369	Leukemia Surveillance Counterpoint: USA. , 2013, , 479-483.		0
370	Systematic analysis of potential targets for immunotherapy in acute myeloid leukemia Journal of Clinical Oncology, 2013, 31, 3104-3104.	1.6	0
371	Minimal residual disease (MRD) status pre- and post- high-dose therapy/autologous stem (HDC/ASCT) cell transplantation for multiple myeloma (MM) in the era of novel agents Journal of Clinical Oncology, 2013, 31, 8605-8605.	1.6	0
372	Early lymphocyte recovery (ELR) impact on disease outcome following autologous hematopoietic stem cell transplantation (HDT/ASCT) for multiple myeloma (MM) in the era of novel agents Journal of Clinical Oncology, 2013, 31, e19539-e19539.	1.6	0
373	Commonly Used Transplant-Related Medications in Long-Term Survivors. , 0, , 385-386.		0
374	A Patient's Perspective: Concepts of Long-Term Survivor Support Groups and Their Roles. , 0, , 376-378.		0
375	Low CD34 Cell Dose Is Associated With Higher Non-Relapse and Overall Mortality After Reduced Intensity Conditioning Hematopoietic Cell Transplantation For Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood, 2013, 122, 3342-3342.	1.4	0
376	Incidence and Risk Factors Associated with Clostridium Difficile Infection in Cord Blood Transplant. Blood, 2014, 124, 3868-3868.	1.4	0
377	Appendix II Follow-up calendar after allogeneic stem cell transplantation in lymphoma. , 0, , 263-264.		0
378	Appendix I Follow-up calendar after autologous stem cell transplantation in lymphoma. , 0, , 261-261.		0

#	Article	IF	CITATIONS
379	First 100 days of the allogeneic hematopoietic stem cell transplantation process in lymphoma. , 0, , 113-117.		Ο
380	First 100 days of the autologous hematopoietic stem cell transplantation process in lymphoma. , 0, , 109-112.		0
381	Outcomes of Venous Thromboembolism in Hospitalized Non-Hodgkin Lymphoma Patients: Analysis from the Nationwide Inpatient Sample Database. Blood, 2015, 126, 5058-5058.	1.4	Ο
382	In the Era of Bortezomib-Based Chemotherapy the Presence of Minimal Residual Disease Predicts Progression Free Survival after Autologous Hematopoietic Cell Transplant. Blood, 2015, 126, 5493-5493.	1.4	0
383	Myeloablative Versus Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia in Patients with Prior Myelodysplastic Syndrome/ Myeloproliferative Disorders: An ALWP of EBMT Study. Blood, 2017, 130, 907-907.	1.4	Ο
384	Donor Age Determines Outcome in Acute Leukemia Patients Undergoing Haploidentical Hematopoietic Cell Transplantation. Blood, 2017, 130, 850-850.	1.4	0
385	The Essentials of Drug Interactions in Hematopoietic Stem Cell Transplantation. Clinical Hematology International, 2019, 1, 124-126.	1.7	Ο
386	Clinical Hematology International: Why a New Journal in Hematology?. Clinical Hematology International, 2019, 1, 1.	1.7	0
387	Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation from HLA-Identical Sibling Donors: A Retrospective Analysis from the Acute Leukemia Working Party of the EBMT. Blood, 2019, 134, 148-148.	1.4	Ο
388	Underdiagnosed Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome(VOD/SOS) As a Major Cause of Multi-Organ Failure in Acute Leukemia Transplant Patients: An Analysis from the EBMT Acute Leukemia Working Party. Blood, 2019, 134, 4483-4483.	1.4	0
389	Post-Transplant Cyclophosphamide after Matched Sibling, Unrelated and Haploidentical Donor Transplants in Patients with Acute Myeloid Leukemia, a Comparative Study of the ALWP EBMT. Blood, 2019, 134, 3274-3274.	1.4	Ο
390	Outcomes of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning Regimen in Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide for Acute Myelogenous Leukemia: ALWP of the EBMT Study. Blood, 2019, 134, 4584-4584.	1.4	0
391	Reduced Risk of Relapse for Total Body Irradiation + Fludarabine Compared to Busulphan + Fludarabine As "Reduced-Toxicity" Conditioning for Patients with Acute Myeloid Leukemia Treated with Allohsct in First Complete Remission. a Study By the Acute Leukemia Working Party of the EBMT. Blood, 2019, 134, 255-255	1.4	Ο
392	Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia and Karnofsky Performance Status Score Equal or Lower Than 80%. a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Blood, 2019, 134, 3327-3327.	1.4	0
393	The Disease-Risk Stratification Scheme (DRSS), a Contemporary Risk-Stratification System for Allogeneic Stem Cell Transplantation. Blood, 2019, 134, 43-43.	1.4	Ο
394	Impact of Renal Dysfunction Measured By Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation (HCT). Blood, 2019, 134, 3256-3256.	1.4	0
395	Venetoclax-Based Salvage Therapy for Post-Hematopoietic Cell Transplantation Relapse in Acute Myeloid Leukemia. Blood, 2019, 134, 2643-2643.	1.4	0
396	Lower Hematopoietic Progenitor Cell Counts and Yields at Subsequent Donations Is Influenced By a Shorter Inter-Donation Interval between the First and Subsequent Mobilizations. Blood, 2019, 134, 1962-1962.	1.4	0

#	Article	IF	CITATIONS
397	Effectiveness of COVIDâ€19 vaccination in patients after allogeneic haematopoietic cell transplant: how much protection are we getting?. British Journal of Haematology, 2021, , .	2.5	0
398	Reduced Intensity Vs. Non-Myeloablative Conditioning Regimens for Haploidentical Transplantation in Complete Remission Acute Myeloid Leukemia: A Study from the ALWP of the EBMT. Blood, 2020, 136, 9-9.	1.4	0
399	Non-Infectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation (HCT): A Center for International Blood and Marrow Transplant Research (CIBMTR) Study. Blood, 2020, 136, 7-8.	1.4	0
400	Increased Incidence of New-Onset Diabetes Mellitus Type II Following Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease. Blood, 2020, 136, 20-20.	1.4	0
401	Reduced Insulin Sensitivity in Patients with Myeloid Malignancies and Clonal Hematopoiesis Mutations. Blood, 2020, 136, 27-28.	1.4	0
402	Reduction in Prevalence of Thrombotic Events in Sickle Cell Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 12-12.	1.4	0
403	Expanded Comorbidity Definitions Improve Application of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for Children and Young Adults with Non-Malignant Diseases Receiving Allogeneic Hematopoietic Cell Transplantation. Blood, 2020, 136, 7-8.	1.4	0
404	Outcomes of Allogeneic Hematopoietic Cell Transplantation with Cord Blood Versus Mismatched Unrelated Donor with Post-Transplant Cyclophosphamide in Acute Myeloid Leukemia: An Analysis from the ALWP of the EBMT. Blood, 2020, 136, 5-6.	1.4	0
405	Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis. Bone Marrow Transplantation, 2022, , .	2.4	0